Eli Lilly & Company Chairman and CEO Dave Ricks sheds light on growth and success, the increase in weight loss drug ...

In obesity, Lilly removed a dual amylin calcitonin receptor agonist (DACRA) from its phase 1 pipeline. Lilly got into DACRAs by partnering with KeyBioscience in 2017. At one time, the Big Pharma was ...

Matt Price drove his 73-year-old father Stephen from their New Jersey home to a medical strip mall on the Jersey Shore, for ...

The Washington University trial comes as part of a larger platform study which hopes to understand if Alzheimer's disease can ...

Some two years into Leqembi’s launch, Eisai continues to go all-in on its Alzheimer’s disease-fighting antibody, which the ...

Eli Lilly's strong momentum in blockbuster therapies and promising pipeline signals future growth, but competition and ...

Scientists are testing an experimental anti-amyloid antibody in people expected to develop early-onset Alzheimer's.

The first participants in an international clinical trial aimed at preventing Alzheimer’s disease in young adults at high ...

Weight loss drugs are huge these days, and Eli Lilly (LLY) is leading the pack when it comes to these. However, today’s ...

From revenue to R&D investment, Novo and Lilly and their mega-blockbuster weight loss drugs Zepbound and Wegovy have moved ...

A US university has launched a prevention trial examining the use of Eli Lilly’s investigational remternetug in young adults to prevent further development of Alzheimer’s disease. Washington ...